Arun J. Sanyal

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.

Evaluation and management of non-alcoholic steatohepatitis.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy.

Management of ascites in cirrhosis.

Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.

Hepatorenal syndrome.

Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.

Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.

Physiologic concentrations of leptin increase collagen production by non-immortalized human hepatic stellate cells.

Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.

MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy.

Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection.

Sepsis-induced cholestasis.

Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.

Acute variceal hemorrhage.

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.

Recurrent flares of pancreatitis predict development of exocrine insufficiency in chronic pancreatitis.

A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.

The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome.

A lipidomic analysis of nonalcoholic fatty liver disease.

Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease.

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years.

Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Sepsis and cholestasis.

Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis.

Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.

Portal hypertension and variceal hemorrhage.

Recent advances in nonalcholic fatty liver disease.

Hepatitis C virus infection: molecular pathways to metabolic syndrome.

Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways.

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Portal hypertension and its complications.

A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.

Hepatitis C infection and nonalcoholic fatty liver disease.

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Fatty liver disease.

Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.

Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.

Coagulation and hemostasis in liver disease: controversies and advances. Preface.

Coagulation disorders and bleeding in liver disease: future directions.

Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data.

Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes.

The effect of fatigue on driving skills in patients with hepatic encephalopathy.

Effect of hyponatraemia on outcomes following orthotopic liver transplantation.

Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Recent advances in nonalcoholic fatty liver disease.

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

Ascites: diagnosis and management.

Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test.

HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy.

Endoplasmic reticulum stress and the unfolded protein response.

Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective.

Sirtuins and the hepatic regulation of energy homeostasis.

The plasma lipidomic signature of nonalcoholic steatohepatitis.

Recent advances in nonalcoholic fatty liver disease.

Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

The Institute of Medicine report on viral hepatitis: a call to action.

Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

Use of desirability functions to evaluate health status in patients with cirrhosis.

Role of microRNAs in non-alcoholic steatohepatitis.

Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.

An explicit quality indicator set for measurement of quality of care in patients with cirrhosis.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis.

The treatment of hepatic encephalopathy in the cirrhotic patient.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Cirrhotic cardiomyopathy.

Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples.

Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C.

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.

Novel treatment modalities for nonalcoholic steatohepatitis.

The etiology of hepatocellular carcinoma and consequences for treatment.

Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers.

Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis.

Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography.

NASH: A global health problem.

Lipotoxicity in NASH.

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Driving simulation can improve insight into impaired driving skills in cirrhosis.

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.

Pentoxifylline for steatohepatitis: magic bullet or smoking gun?

Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.

Pathophysiology guided treatment of nonalcoholic steatohepatitis.

Association between puberty and features of nonalcoholic fatty liver disease.

Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.

Association of AKI with mortality and complications in hospitalized patients with cirrhosis.

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD).

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study.

Scavenger receptor A restrains T-cell activation and protects against concanavalin A-induced hepatic injury.

Preface. Advances and evolving concepts in nonalcoholic fatty liver disease.

Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells.

Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).

Vitamin E and nonalcoholic fatty liver disease.

The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice.

5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

The molecular pathogenesis of cholestasis in sepsis.

The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy.

Multiple classes of environmental chemicals are associated with liver disease: NHANES 2003-2004.

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival.

Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease.

Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.

The global NAFLD epidemic.

Drug-induced steatohepatitis.

Mechanisms of obesity-induced gastrointestinal neoplasia.

Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.

Diagnosis of covert hepatic encephalopathy without specialized tests.

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.

Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models.

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.

Colonic inflammation and secondary bile acids in alcoholic cirrhosis.

Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury.

Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells.

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Long term changes in liver histology following treatment of chronic hepatitis C virus.

Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.

Validation of noninvasive methods for detecting hepatic steatosis in patients with human immunodeficiency virus infection.

Trials and tribulations in drug development for nonalcoholic steatohepatitis.

KEAP the balance between life and death.

Effects of obstructive sleep apnea on sleep quality, cognition, and driving performance in patients with cirrhosis.

Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.

Urinary biomarkers and progression of AKI in patients with cirrhosis.

Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.

Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S.

Transjugular intrahepatic portosystemic shunt.

Nonendoscopic management strategies for acute esophagogastric variceal bleeding.

Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score.

Reply: To PMID 24818764.

Myths and mysteries about staging hepatic fibrosis by fibroscan.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.

Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease.

Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function.

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.

Recent advances in understanding/management of non-alcoholic steatohepatitis.

The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study.

Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.

Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.

Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.

Endoscopic Diagnosis and Therapy in Gastroesophageal Variceal Bleeding.

Novel therapeutic targets for steatohepatitis.

The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease.

An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis.

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.

De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.

Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease.

A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.

Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.

Drug-induced fatty liver disease: An overview of pathogenesis and management.

A model of acute kidney injury in mice with cirrhosis and infection.

In Patients With Cirrhosis, Driving Simulator Performance Is Associated With Real-life Driving.

End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.

Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis.

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.

Management of NAFLD: a stage-based approach.

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese.

Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.

The Worsening Profile of Alcoholic Hepatitis in the United States.

Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.

Preserved hemostatic status in patients with non-alcoholic fatty liver disease.

Liver Transplantation Significantly Improves Global Functioning and Cerebral Processing.

Gut microbiota drive the development of neuro-inflammatory response in cirrhosis.

Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS norms.